1 / 1

Enrolled 95

Enrolled 95. Expansion cohorts*. Dose escalation cohorts. Allocated to BID schedule(n=26) Received OSI-906 (n=24 ). Allocated to BID schedule(n=31) Received OSI-906 (n=29 ). Allocated to QD schedule (n=38) Received OSI-906 (n=33).

alyson
Download Presentation

Enrolled 95

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Enrolled 95 Expansion cohorts* Dose escalation cohorts Allocated to BID schedule(n=26) Received OSI-906 (n=24) Allocated to BID schedule(n=31) Received OSI-906 (n=29) Allocated to QD schedule (n=38) Received OSI-906 (n=33) Discontinued (n=33) Disease progression (n=21) Adverse event (n=7) Medical/ ethical reasons (n=1) Patient request (n=4) Discontinued (n=23) Disease progression (n=17) Adverse event (n=4) Medical/ ethical reasons (n=1) Patient request (n=1) Discontinued (n=28) Disease progression (n=26) Adverse event (n=2) Evaluated for: Safety (n=33) DL T (n=27) Pharmacokinetics (n=33) Efficacy (n=24) Evaluated for: Safety (n=22) DL T (n=22) Pharmacokinetics (n=24) Efficacy (n=19) Evaluated for: Safety (n=29) Pharmacokinetics (n=29) Efficacy (n=22) Figure 1. Patient disposition. *Including nine patients in the diabetes expansion cohort and twenty patients in the biomarker expansion cohort

More Related